Southeast Asset Advisors LLC Boosts Stock Position in Pfizer Inc. $PFE

Southeast Asset Advisors LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 53.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 75,900 shares of the biopharmaceutical company’s stock after acquiring an additional 26,352 shares during the quarter. Southeast Asset Advisors LLC’s holdings in Pfizer were worth $1,934,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Curio Wealth LLC grew its holdings in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares in the last quarter. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Pfizer during the third quarter worth $29,000. Howard Hughes Medical Institute acquired a new stake in shares of Pfizer in the second quarter valued at $30,000. True Wealth Design LLC boosted its holdings in Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares during the period. Finally, Darwin Wealth Management LLC purchased a new stake in Pfizer during the 2nd quarter worth about $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $27.58 on Monday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The firm has a market capitalization of $156.78 billion, a P/E ratio of 20.28 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The company’s fifty day moving average price is $25.81 and its 200 day moving average price is $25.20.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same quarter last year, the company posted $0.63 earnings per share. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. Pfizer’s payout ratio is currently 126.47%.

Wall Street Analyst Weigh In

PFE has been the subject of several recent research reports. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. Morgan Stanley reduced their target price on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Daiwa America cut shares of Pfizer from a “strong-buy” rating to a “hold” rating in a report on Thursday. Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. Finally, Bank of America dropped their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $28.00.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.